China Pharma Holdings (CPHI) Receivables - Other (2016 - 2025)
China Pharma Holdings (CPHI) has disclosed Receivables - Other for 15 consecutive years, with $61275.0 as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Receivables - Other rose 31.62% year-over-year to $61275.0, compared with a TTM value of $61275.0 through Sep 2025, up 31.62%, and an annual FY2024 reading of $30286.0, down 80.82% over the prior year.
- Receivables - Other was $61275.0 for Q3 2025 at China Pharma Holdings, up from $48361.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $1.7 million in Q3 2021 and bottomed at $28660.0 in Q2 2024.
- Average Receivables - Other over 5 years is $551357.2, with a median of $61275.0 recorded in 2025.
- The sharpest move saw Receivables - Other crashed 97.96% in 2022, then skyrocketed 442.04% in 2023.
- Year by year, Receivables - Other stood at $1.4 million in 2021, then plummeted by 97.96% to $29139.0 in 2022, then surged by 442.04% to $157944.0 in 2023, then plummeted by 80.82% to $30286.0 in 2024, then surged by 102.32% to $61275.0 in 2025.
- Business Quant data shows Receivables - Other for CPHI at $61275.0 in Q3 2025, $48361.0 in Q2 2025, and $39046.0 in Q1 2025.